PGT（植入前基因检测）市场：按产品类型、按週期类型、按技术、按程序类型、按应用、按最终用户、按地区，2024-2031 年

PGT（植入前基因检测）市场评估 - 2024-2031

人们对辅助生殖技术 (ART) 的认识和利用不断提高，以及对遗传异常和不孕症的担忧不断增加，正在推动 PGT（植入前基因检测）市场的发展。Verified Market Research分析师表示，预计2031年PGT（植入前基因检测）市场估值为13.3409亿美元，低于2023年6.2191亿美元的估值，预计将达到这一水准。

新一代定序 (NGS) 和阵列比较基因组杂交 (aCGH) 等基因组技术的进步使基因筛检更加准确和全面，加速了市场成长。这将推动市场从2024年到2031年以10.01%的复合年增长率成长。

PGT（植入前基因检测）市场定义/概述

植入前基因检测（PGT）是针对体外受精（IVF）产生的胚胎的专门基因检测过程。在将胚胎放入子宫之前，从每个胚胎中取出一个或几个细胞进行活检，以确定其基因组成。PGT主要用于发现胚胎中的遗传异常、染色体异常或特定基因突变。

此外，这种方法对于有遗传性遗传疾病风险的夫妻、有反覆流产或体外受精失败史的人以及寻求不孕症治疗的老年妇女特别有用。PGT 可以选择没有遗传疾病的胚胎，增加成功怀孕和健康孩子出生的机会。

影响PGT（植入前基因检测）市场成长的推动因素有哪些？

基因检测越来越受到公众的欢迎，因为人们认识到它具有在受精卵的早期阶段检测遗传异常和疾病的优势。这种意识是由于人们对健康婴儿的渴望不断增加，尤其是有遗传病史的夫妇、高龄母亲或经历过多次怀孕失败的夫妇。这种保护子孙后代健康和福祉的愿望一直是建立植入前基因检测（PGT）的关键驱动力。

PGT（植入前基因检测）市场从次世代定序（NGS）、聚合酶炼式反应（PCR）和微阵列方法等基因检测技术的进步中受益匪浅。这些技术提高了基因检测的准确性、效率和速度，使 PGT 更容易取得且可靠。此外，IVF 设备和程序的进步正在支持改进基因检测并促进将 PGT 纳入不孕症治疗。

此外，遗传疾病的全球盛行率正在增加，部分原因是诊断方法的改善和认识的提高。已知有遗传问题家族史或经历过不明原因不孕、流产或死产的夫妇可能会选择PGT，以减少将遗传异常遗传给孩子的机会。这些世代趋势扩大了 PGT 服务的潜在消费者基础，并促使市场成长。

伦理问题是否会限制 PGT（植入前基因检测）的采用？

植入前基因检测（PGT）是一种在怀孕前以体外受精（IVF）评估胚胎是否有遗传问题的过程。这引发了人们对根据遗传特征选择胚胎的伦理担忧，并可能促使 "设计婴儿" 的诞生。使用PGT来避免重大遗传疾病和选择理想的性状之间存在一线之隔，并且存在关于优生学、不公正和偏见的社会、道德和伦理问题，从而限制了市场的成长。

儘管PGT技术已经取得了长足的进步，但它在准确性、效率以及检测多种遗传疾病的能力方面仍然存在局限性。出现假阳性和假阴性，导致存活胚胎被破坏或选择未诊断的遗传异常的胚胎。提高 PGT 的准确性和范围需要持续的研究和开发，这既昂贵又耗时，限制了市场的扩张。

目录

第1章全球PGT（植入前基因检测）市场：简介

• 市场概况
• 调查范围
• 先决条件

第 2 章执行摘要

第3章 验证市场研究研究方法

• 数据挖掘
• 验证
• 一次资料
• 数据源列表

第4章 PGT（植入前基因检测）的全球市场展望

• 概述
• 市场动态
  • 促进因素
  • 阻碍因素
  • 机会
• 波特的五力模型
• 价值链分析
• 监管框架

第5章 PGT（植入前基因检测）的全球市场：副产品

• 概述
• 试剂和耗材
• 检验设备
• 软件和服务

第6章 PGT（植入前基因检测）的全球市场：依週期类型

• 概述
• 新鲜的非捐赠者
• 冷冻非捐赠者
• 新的捐赠者
• 冷冻供体

第7章 依技术划分的 PGT（植入前基因检测）全球市场

• 概述
• 下一代测序 (NGS)
• 聚合酶炼式反应 (PCR)
• 萤光原位杂交
• 比较基因组杂交
• 单核甘酸多态性

第8章 PGT（植入前基因检测）的全球市场：按程序类型

• 概述
• 植入前基因筛检
• 植入前遗传学诊断

第9章 PGT（植入前基因检测）的全球市场：依应用分类

• 概述
• 非整倍体
• 染色体结构异常
• 单基因异常
• X连锁疾病
• HLA分型
• 性别认同

第10章 PGT（植入前基因检测）的全球市场：依最终用户分类

• 概述
• 生育诊所
• 医院
• 诊断实验室
• 其他最终用户

第11章 PGT（植入前基因检测）全球市场（按地区）

• 概述
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 亚太其他地区
• 世界其他地区
  • 拉丁美洲
  • 中东/非洲

第12章 全球PGT（植入前基因检测）市场竞争态势

• 概述
• 企业市占率
• 供应商情况
• 主要发展策略

第13章 公司简介

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Perkinelmer, Inc.
• Coopersurgical, Inc.
• Abbott Laboratories
• Natera, Inc.
• Rubicon Genomics
• Oxford Gene Technology
• Yikon Genomics
• Scigene
• Beijing Genomics Institute
• Good Start Genetics
• Invicta Genetics
• Combimatrix
• Genea Limited
• Progenesis

第14章附录

• 相关报导

Preimplantation Genetic Testing Market Valuation - 2024-2031

The growing awareness and use of assisted reproductive technologies (ART), along with increased occurrences of genetic abnormalities and infertility concerns, is propelling the preimplantation genetic testing (PGT) market. According to the analyst from Verified Market Research, the Preimplantation Genetic Testing Market is estimated to reach a valuation of USD 1334.09 Million in 2031 over the forecast subjugating around USD 621.91 Million valued in 2023.

Advancements in genomic technologies, such as next-generation sequencing (NGS) and array comparative genomic hybridization (aCGH), are allowing for more precise and comprehensive genetic screening, accelerating market growth. It enables the market to grow at a CAGR of 10.01% from 2024 to 2031.

Preimplantation Genetic Testing Market: Definition/Overview

Preimplantation Genetic Testing (PGT) is a specialized genetic testing process for embryos generated through in vitro fertilization (IVF). Before being put into the uterus, one or a few cells from each embryo are biopsied to determine their genetic makeup. PGT is primarily used to discover genetic abnormalities, chromosomal problems, or specific genetic mutations in embryos, allowing prospective parents to make educated decisions about embryo selection for implantation.

Furthermore, this method is especially useful for couples at risk of passing on genetic illnesses, individuals with a history of recurrent pregnancy loss or unsuccessful IVF attempts, and older women seeking fertility treatments. PGT allows for the selection of embryos free of genetic diseases, boosting the chances of a successful pregnancy and the birth of a healthy child.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Which are the Drivers Influencing the Growth of the Preimplantation Genetic Testing Market?

Genetic testing is gaining popularity among the general public, owing to a better understanding of its benefits in detecting genetic abnormalities and ailments early in the embryonic stage. This awareness is accompanied by a rising preference for healthy babies, particularly among couples with a history of genetic diseases, those of advanced maternal age, or those who have experienced several pregnancy losses. This desire to protect future generations' health and well-being is an important driver to establishing preimplantation genetic testing (PGT).

The Preimplantation Genetic Testing Market has profited greatly from advances in genetic testing technologies such as Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Microarray methods. These technologies have increased the accuracy, efficiency, and speed of genetic testing, making PGT more accessible and dependable. Furthermore, advances in IVF equipment and procedures support these genetic testing improvements, making it easier to incorporate PGT into fertility treatments.

Furthermore, the global prevalence of genetic illnesses is increasing, owing in part to improved diagnosis procedures and more awareness. Couples with known genetic problems in their families, as well as those who have had unexplained infertility, miscarriages, or stillbirths, are more likely to choose PGT to lower the possibility of transferring genetic abnormalities to their children. This generational trend broadens the potential consumer base for PGT services, resulting in market growth.

Will Ethical Concerns Restrain Adoption of Preimplantation Genetic Testing?

Preimplantation genetic testing (PGT) is the process of evaluating embryos for genetic problems before to pregnancy using in vitro fertilization. This raises ethical concerns about selecting embryos based on genetic features, which might lead to "designer babies." There is a narrow line between utilizing PGT to avoid major genetic illnesses and choosing desirable features, which creates social, moral, and ethical concerns about eugenics, injustice, and prejudice, thereby limiting market growth.

While PGT technologies have made tremendous advances, they still have limits in terms of accuracy, efficiency, and capacity to detect a wide spectrum of genetic disorders. False positives or negatives occur, resulting in the destruction of viable embryos or the selection of embryos with undiagnosed genetic abnormalities. Improving the accuracy and scope of PGT necessitates continual research and development, which is expensive and time-consuming, limiting market expansion.

Category-wise Acumens

How does the Dominance of the Reagents and Consumables Impact the Market?

According to VMR analyst, the reagents and consumables segment is anticipated to dominate the segment within the Preimplantation Genetic Testing Market. Reagents and consumables are required at all stages of the PGT process, from DNA amplification to analysis. These items are used in big quantities and require regular replenishment, resulting in a steady demand. Unlike instruments, which are long-term capital investments, reagents and consumables are continuing operating expenses for genetic testing laboratories. This large volume utilization greatly increases their market share.

The field of genetic testing, including PGT, is quickly growing, with ongoing advances and breakthroughs in reagents and consumables. These advancements have the potential to improve the accuracy, speed, and efficiency of testing processes. Also, the flexibility to tailor reagents and consumables to specific tests or conditions helps accelerate their adoption, addressing the precise requirements of PGT laboratories and clinics.

Furthermore, reagents and consumables are used in a variety of PGT procedures, including Preimplantation Genetic Screening (PGS) for aneuploidy detection, Preimplantation Genetic Diagnosis (PGD) for single gene diseases, and newer approaches for structural rearrangements and mitochondrial illnesses. These products' market domination is due to their adaptability and requirement in a variety of PGT applications.

How does the Rising Awareness of Genetic Disorders Contribute to the PGD Segment?

The preimplantation genetic diagnosis (PGD) segment is estimated to hold the largest share of the Preimplantation Genetic Testing Market during the forecast period. PGD is utilized specifically by couples who are known to have a high chance of passing on specific genetic disorders to their children. This specialized approach to testing detects single-gene disorders and chromosomal anomalies unique to the parents' genetic origins, making it an essential tool for families looking to avoid the transfer of hereditary diseases. The need for PGD stems from its capacity to bring peace of mind to at-risk couples by ensuring the birth of healthy offspring free of specific genetic abnormalities.

Furthermore, the general public and healthcare professionals are becoming increasingly aware of the benefits of genetic testing in preventing inherited disorders. This awareness, combined with the rising occurrence of genetic abnormalities due to a variety of reasons, including longer parental ages at conception, has resulted in increased demand for PGD. Prospective parents are becoming more knowledgeable and proactive about their reproductive options, resulting in an increase in the use of PGD to assure the health and well-being of their future offspring.

Country/Region-wise Acumens

How will Demand for Preimplantation Genetic Testing Shape the North American Market?

According to VMR analysis, the North American region is estimated to dominate in Preimplantation Genetic Testing Market during the forecast period. Genetic testing and its benefits are widely understood and accepted in North America. This is due in part to healthcare providers' educational efforts, patient group activism, and media and popular culture coverage. As a result, there is a high demand for genetic testing services, including PGT, among people and couples seeking to uncover genetic abnormalities, assess risks to future children, and make educated reproductive decisions. This desire is amplified by the cultural acceptance of IVF and related reproductive technologies.

Furthermore, North America, particularly the United States, has some of the world's most advanced healthcare infrastructure, with cutting-edge medical facilities, leading-edge research institutions, and a strong emphasis on new healthcare solutions. This infrastructure facilitates considerable research and development efforts in genetic testing and reproductive technologies. Furthermore, substantial healthcare expenditure in the region, both public and private, allows for significant investment in new technology and treatments, making modern PGT services broadly available to patients.

Will the Asia Pacific prove Opportunistic for the Preimplantation Genetic Testing Market?

Asia Pacific is estimated to grow at the highest CAGR in the Preimplantation Genetic Testing Market. This region has experienced substantial growth in awareness and acceptance of genetic testing and its potential advantages. This is attributable to improved knowledge, more access to information via digital platforms, and government-led initiatives to promote genetic health. As a result, more people and couples are using PGT as part of their family planning, increasing market demand.

Furthermore, governments around Asia Pacific are making significant investments in healthcare infrastructure as well as encouraging biotechnology and genetic engineering research. Countries such as China, Japan, South Korea, and Singapore are setting the standard for enacting policies that encourage the adoption of modern medical technology, including PGT. These measures, combined with supporting legislative frameworks, are considerably boosting the region's PGT market.

Competitive Landscape

The competitive landscape of the preimplantation genetic testing (PGT) market is marked by a constant interplay of technology breakthroughs, regulatory frameworks, and shifting customer preferences. Furthermore, cooperation among healthcare providers, research institutions, and technology companies are pushing innovation and broadening the use of PGT beyond typical genetic disorders to include broader genomic profiling.

Some of the prominent players operating in the Preimplantation Genetic Testing Market include:

Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., PerkinElmer Inc., CooperSurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Scigene, Beijing Genomics Institute, Good Start Genetics, Invicta Genetics, Combimatrix, Genea Limited, Progenesis, Igenomix.

Latest Developments:

In April 2023, Eurofins Genoma, a leader in the PGT market, launched niPGT-A, a non-invasive preimplantation genetic aneuploidy screening test. This new test analyses cell-free foetal DNA in the maternal bloodstream, providing a less intrusive option for couples undergoing in vitro fertilization (IVF).

In April 2023, LifeView, powered by Genomic Prediction, announced a partnership with Ovation Fertility. This agreement gives Ovation patients access to the LifeView PGT Platform, which provides cutting-edge technology and might significantly improve their clinical care experience.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PREIMPLANTATION GENETIC TESTING MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis
• 4.5 Regulatory Framework

5 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Reagents and Consumables
• 5.3 Instruments
• 5.4 Software and Services

6 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY CYCLE TYPE

• 6.1 Overview
• 6.2 Fresh Non-donor
• 6.3 Frozen Non-donor
• 6.4 Fresh Donor
• 6.5 Frozen Donor

7 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY

• 7.1 Overview
• 7.2 Next-generation Sequencing (NGS)
• 7.3 Polymerase Chain Reaction (PCR)
• 7.4 Fluorescence In Situ Hybridization
• 7.5 Comparative Genomic Hybridization
• 7.6 Single-nucleotide Polymorphism

8 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE

• 8.1 Overview
• 8.2 Preimplantation Genetic Screening
• 8.3 Preimplantation Genetic Diagnosis

9 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION

• 9.1 Overview
• 9.2 Aneuploidy
• 9.3 Structural Chromosomal Abnormalities
• 9.4 Single Gene Disorders
• 9.5 X-linked Disorders
• 9.6 HLA Typing
• 9.7 Gender Identification

10 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY END-USER

• 10.1 Overview
• 10.2 Fertility Clinics
• 10.3 Hospitals
• 10.4 Diagnostic Laboratories
• 10.5 Other End Users

11 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY GEOGRAPHY

• 11.1 Overview
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 U.K.
  • 11.3.3 France
  • 11.3.4 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Rest of Asia Pacific
• 11.5 Rest of the World
  • 11.5.1 Latin America
  • 11.5.2 Middle East and Africa

12 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET COMPETITIVE LANDSCAPE

• 12.1 Overview
• 12.2 Company Market Share
• 12.3 Vendor Landscape
• 12.4 Key Development Strategies

13 COMPANY PROFILES

• 13.1 Illumina, Inc.
  • 13.1.1 Overview
  • 13.1.2 Financial Performance
  • 13.1.3 Product Outlook
  • 13.1.4 Key Developments
• 13.2 Thermo Fisher Scientific Inc.
  • 13.2.1 Overview
  • 13.2.2 Financial Performance
  • 13.2.3 Product Outlook
  • 13.2.4 Key Developments
• 13.3 Agilent Technologies, Inc.
  • 13.3.1 Overview
  • 13.3.2 Financial Performance
  • 13.3.3 Product Outlook
  • 13.3.4 Key Developments
• 13.4 Perkinelmer, Inc.
  • 13.4.1 Overview
  • 13.4.2 Financial Performance
  • 13.4.3 Product Outlook
  • 13.4.4 Key Developments
• 13.5 Coopersurgical, Inc.
  • 13.5.1 Overview
  • 13.5.2 Financial Performance
  • 13.5.3 Product Outlook
  • 13.5.4 Key Developments
• 13.6 Abbott Laboratories
  • 13.6.1 Overview
  • 13.6.2 Financial Performance
  • 13.6.3 Product Outlook
  • 13.6.4 Key Developments
• 13.7 Natera, Inc.
  • 13.7.1 Overview
  • 13.7.2 Financial Performance
  • 13.7.3 Product Outlook
  • 13.7.4 Key Developments
• 13.8 Rubicon Genomics
  • 13.8.1 Overview
  • 13.8.2 Financial Performance
  • 13.8.3 Product Outlook
  • 13.8.4 Key Developments
• 13.9 Oxford Gene Technology
  • 13.9.1 Overview
  • 13.9.2 Financial Performance
  • 13.9.3 Product Outlook
  • 13.9.4 Key Developments
• 13.10 Yikon Genomics
  • 13.10.1 Overview
  • 13.10.2 Financial Performance
  • 13.10.3 Product Outlook
  • 13.10.4 Key Developments
• 13.11 Scigene
  • 13.11.1 Overview
  • 13.11.2 Financial Performance
  • 13.11.3 Product Outlook
  • 13.11.4 Key Developments
• 13.12 Beijing Genomics Institute
  • 13.12.1 Overview
  • 13.12.2 Financial Performance
  • 13.12.3 Product Outlook
  • 13.12.4 Key Developments
• 13.13 Good Start Genetics
  • 13.13.1 Overview
  • 13.13.2 Financial Performance
  • 13.13.3 Product Outlook
  • 13.13.4 Key Developments
• 13.14 Invicta Genetics
  • 13.14.1 Overview
  • 13.14.2 Financial Performance
  • 13.14.3 Product Outlook
  • 13.14.4 Key Developments
• 13.15 Combimatrix
  • 13.15.1 Overview
  • 13.15.2 Financial Performance
  • 13.15.3 Product Outlook
  • 13.15.4 Key Developments
• 13.16 Genea Limited
  • 13.16.1 Overview
  • 13.16.2 Financial Performance
  • 13.16.3 Product Outlook
  • 13.16.4 Key Developments
• 13.17 Progenesis
  • 13.17.1 Overview
  • 13.17.2 Financial Performance
  • 13.17.3 Product Outlook
  • 13.17.4 Key Developments

14 Appendix

• 14.1 Related Reports